Business Case

Estimated NSCLC burden in Mexico based on RWE to inform clinical management and drive market share of more effective therapies

Our client, a large, international pharmaceutical company hypothesized existing NSCLC clinical management was not optimized and expressed an interest in analyzing RWE to understand the burden of NSCLC in Mexico. LSC’s expertise facilitated the collection and analysis of Mexican RWE, ultimately producing a multi-variate model illuminating the clinical, economic, and social implications of current NSCLC clinical management practices in the country and informing policy makers of specific, tangible therapy changes that could improve outcomes in the country.